2022 FDA TIDES (Peptides and Oligonucleotides) Harvest-Reference-Cited by-同舟云学术

2022 FDA TIDES (Peptides and Oligonucleotides) Harvest

Published:2023-02-22 Issue:3 Volume:16 Page:336
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Al Musaimi Othman¹^ORCID,Al Shaer Danah²^ORCID,Albericio Fernando³⁴^ORCID,de la Torre Beatriz G.⁵^ORCID

Affiliation:

1. Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK

2. Department of Medicinal Chemistry, Evotec (UK) Ltd., Abingdon OX14 4R, UK

3. School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa

4. CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain

5. KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa

Abstract

A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-class and thus received fast-track designation by the FDA in categories such as breakthrough therapy, priority review voucher, orphan drug, accelerated approval, and so on. Here, we analyze the TIDES approved in 2022 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.

Funder

National Research Foundation

University of KwaZulu-Natal

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://www.mdpi.com/1424-8247/16/3/336/pdf

Reference45 articles.

1. de la Torre, B.G., and Albericio, F. (2023). The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 28.

2. de la Torre, B.G., and Albericio, F. (2022). The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 27.